What biopharma companies need to know about this evolving regulatory pathway. The FDA’s latest draft guidance on accelerated approval for new drugs, “Expedited Program for Serious ...
In today's Pharmaceutical Executive Daily, FDA's advisory committee votes in favor of Replimune's RP1 efficacy data in advanced melanoma, three clinical-stage biopharmaceutical companies file for IPOs ...
Vogenx estimates net proceeds of approximately $67.8 million based on an assumed offering price of $12.00 per share. 3 Vogenx is a clinical-stage biopharmaceutical company focused on disorders linked ...
Learn why reshoring and tariff exposure are accelerating the trend toward manufacturing in the market where a product is sold. Understand the significance of the Section 301 investigation into Germany ...
In today's Pharmaceutical Executive Daily, FDA's advisory committee votes in favor of Replimune's RP1 efficacy data in advanced melanoma, three clinical-stage biopharmaceutical companies file for IPOs ...
CTGTAC endorsed that single-arm Ignyte response rate and durability support clinically meaningful systemic antitumor activity attributable to intratumoral RP1 combined with nivolumab in ...
Pharmaceutical Executive spoke with John Standford, executive director of Incubate, about the rise of China as an R&D partner and the US government’s responses. According to him, years of investment ...
Formulary decisions commonly restrict access to T2D and weight loss, creating coverage blind spots as GLP-1 trials mature across broader cardiometabolic and organ-protection indications. Utilization ...
Understand how patient advocacy groups are weighing MFN's affordability promise against other access issues like Medicaid community engagement requirements. Learn why international reference pricing ...
This past May, Pharmaceutical Executive reported that CVS Health decided to return Eli Lilly’s Zepbound to its list of ...
TruTechnologies’ Dr. Richard Graham explains where he sees the actual issues that need to be addressed at FDA. FDA’s latest initiative to improve the drug approval process is Project Trialblazer. The ...
Within your prior big pharma employers, AI is now a core competitive capability as it has shortened target identification and optimized molecule design. As building world-class AI drug-discovery ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results